NDAORALTABLET
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
PREFEST (estradiol; norgestimate) by Teva is characteristics. Approved for moderate to severe vasomotor symptoms due to menopause (). First approved in 1999.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREFEST is an oral hormone replacement therapy combining estradiol and norgestimate, indicated for moderate to severe vasomotor symptoms due to menopause. Estradiol is the principal intracellular human estrogen that binds nuclear receptors in estrogen-responsive tissues to modulate gonadotropin secretion and reduce elevated LH and FSH in postmenopausal women. Norgestimate provides progestin protection in combination therapy.
$0.157MPart D
LOE ApproachingDeclining
Product in late-stage lifecycle with minimal Part D claims (363 in 2023), indicating shrinking patient base and reduced commercial investment needs.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (1)
Worked on PREFEST at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.